| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Robyn A Puffenbarge. Molecular biology of the enzymes that degrade endocannabinoids. Current drug targets. CNS and neurological disorders. vol 4. issue 6. 2006-02-07. PMID:16375680. |
direct manipulation of endocannabinoid tone, therefore, may relieve disease symptoms related to analgesia, obesity, alzheimer's and parkinson's in humans. |
2006-02-07 |
2023-08-12 |
Not clear |
| Belén G Ramírez, Cristina Blázquez, Teresa Gómez del Pulgar, Manuel Guzmán, María L de Ceballo. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 25. issue 8. 2005-10-26. PMID:15728830. |
prevention of alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. |
2005-10-26 |
2023-08-12 |
rat |
| M R Pazos, E Núñez, C Benito, R M Tolón, J Romer. Role of the endocannabinoid system in Alzheimer's disease: new perspectives. Life sciences. vol 75. issue 16. 2004-09-30. PMID:15306158. |
role of the endocannabinoid system in alzheimer's disease: new perspectives. |
2004-09-30 |
2023-08-12 |
Not clear |
| M R Pazos, E Núñez, C Benito, R M Tolón, J Romer. Role of the endocannabinoid system in Alzheimer's disease: new perspectives. Life sciences. vol 75. issue 16. 2004-09-30. PMID:15306158. |
we have recently reported the existence of profound changes in the location and density of several elements of this system in alzheimer's disease tissue samples, indicating that a non-neuronal endocannabinoid system is up-regulated in activated glia. |
2004-09-30 |
2023-08-12 |
Not clear |
| F Nauck, E Klaschi. [Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients]. Schmerz (Berlin, Germany). vol 18. issue 3. 2004-08-18. PMID:15221423. |
compared to placebo, higher efficacy of cannabinoids could be demonstrated in patients with aids as well as in patients with morbus alzheimer. |
2004-08-18 |
2023-08-12 |
Not clear |
| Cristina Benito, Estefanía Núñez, Rosa M Tolón, Erica J Carrier, Alberto Rábano, Cecilia J Hillard, Julián Romer. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 23. issue 35. 2003-12-23. PMID:14657172. |
cannabinoid cb2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in alzheimer's disease brains. |
2003-12-23 |
2023-08-12 |
human |
| Cristina Benito, Estefanía Núñez, Rosa M Tolón, Erica J Carrier, Alberto Rábano, Cecilia J Hillard, Julián Romer. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 23. issue 35. 2003-12-23. PMID:14657172. |
we have studied the status of some of the components of the endocannabinoid system, fatty acid amide hydrolase and cannabinoid cb1 and cb2 receptors, in postmortem brains from patients with alzheimer's disease. |
2003-12-23 |
2023-08-12 |
human |
| J Fernández-Ruiz, I Lastres-Becker, A Cabranes, S González, J A Ramo. Endocannabinoids and basal ganglia functionality. Prostaglandins, leukotrienes, and essential fatty acids. vol 66. issue 2-3. 2002-12-06. PMID:12052041. |
however, other neurological pathologies, such as alzheimer's disease or multiple sclerosis, which are not motor disorders in origin, but present a strong alteration in the control of movement, have also been a subject of interesting research for a cannabinoid therapy. |
2002-12-06 |
2023-08-12 |
human |
| E Po. Dexanabinol Pharmos. Current opinion in investigational drugs (London, England : 2000). vol 1. issue 4. 2001-04-19. PMID:11249704. |
dexanabinol is a non-psychotropic cannabinoid nmda receptor antagonist under development by pharmos corp for the potential treatment of cerebral ischemia, glaucoma, alzheimer's disease, cardiac failure, head injury and multiple sclerosis (ms) [311522]; it is in phase iii trials for traumatic brain injury (tbi) [388709]. |
2001-04-19 |
2023-08-12 |
Not clear |
| T M Westlake, A C Howlett, T I Bonner, L A Matsuda, M Herkenha. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience. vol 63. issue 3. 1995-04-26. PMID:7898667. |
in vitro binding of [3h]cp-55,940, a synthetic cannabinoid, was examined by autoradiography in fresh frozen brain sections from normal aged humans (n = 3), patients who died with alzheimer's disease (n = 5) and patients who died with other forms of cortical pathology (n = 5). |
1995-04-26 |
2023-08-12 |
human |